Literature DB >> 28493533

Combination diagnosis of multi-slice spiral computed tomography and secretary phospholipase A2-IIa for solitary pulmonary nodules.

Hongjun Hou1, Zushan Xu1, Hongsheng Zhang1, Yan Xu2.   

Abstract

INTRODUCTION: This study was aimed to compare the diagnostic value of multi-slice spiral computed tomography (CT) and secretary phospholipase A2-IIa (sPLA2-IIa) in differentiating between malignant and benign solitary pulmonary nodules (SPNs).
METHODS: A total of 223 patients with SPNs (91 patients with malignant SPNs and 132 patients with benign SPNs) were included from Weihai Central Hospital during October 2014 to December 2016. SPN diagnosis was confirmed in all patients using needle biopsy, surgery and bronchoscopy. The patients were managed with dynamic multi-slice CT scans, and their sPLA2-IIa levels were also detected. By selecting the area of interest of focus, the perfusion parameters of multi-slice CT targeting the focus were obtained.
RESULTS: The levels of MTT, PS, BV, BF and sPLA2-IIa significantly increased with increasing severity of SPNs (P<.05). Notably, BV (area under the ROC curve [AUC]=0.915; 95%CI: 0.88-0.95; sensitivity=91.21%; specificity=78.79%) showed a higher potential to discriminate patients with malignant SPNs from those with benign SPNs than did BF (AUC=0.712; 95%CI: 0.65-0.78; sensitivity=72.50%; specificity=59.10%), PS (AUC=0.772; 95%CI: 0.71-0.84; sensitivity=65.93%; specificity=82.58%) and MTT (AUC=0.600; 95%CI: 0.52-0.68; sensitivity=52.75%; specificity=78.03%). Finally, the combined diagnostic value of BV and sPLA2-IIa was quite ideal (AUC=0.947; 95%CI: 0.92-0.97; sensitivity=85.70%; specificity=92.70%) for malignant and benign SPNs.
CONCLUSIONS: The combined diagnostic value of BV and sPLA2-IIa appeared as a desirable detection method for malignant and benign SPNs.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  combined diagnosis; multi-slice spiral computed tomography; secretary phospholipase A2-IIa; sensitivity; solitary pulmonary nodules

Mesh:

Substances:

Year:  2017        PMID: 28493533      PMCID: PMC6817176          DOI: 10.1002/jcla.22250

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  19 in total

Review 1.  Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?

Authors:  Hans W M Niessen; Paul A J Krijnen; Cees A Visser; Chris J L M Meijer; C Erik Hack
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

Review 2.  Multidetector-row CT of the solitary pulmonary nodule.

Authors:  Beatrice Trotman-Dickenson; Bernhard Baumert
Journal:  Semin Roentgenol       Date:  2003-04       Impact factor: 0.800

3.  Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.

Authors:  J R Graff; B W Konicek; J A Deddens; M Chedid; B M Hurst; B Colligan; B L Neubauer; H W Carter; J H Carter
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

4.  Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project.

Authors:  Tomotaka Sobue; Noriyuki Moriyama; Masahiro Kaneko; Masahiko Kusumoto; Toshiaki Kobayashi; Ryosuke Tsuchiya; Ryutaro Kakinuma; Hironobu Ohmatsu; Kanji Nagai; Hiroyuki Nishiyama; Eisuke Matsui; Kenji Eguchi
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

5.  Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism.

Authors:  Ukihide Tateishi; Hiroshi Nishihara; Eriko Tsukamoto; Toshiaki Morikawa; Nagara Tamaki; Kazuo Miyasaka
Journal:  J Comput Assist Tomogr       Date:  2002 Mar-Apr       Impact factor: 1.826

6.  Group II phospholipase A2 in human male reproductive organs and genital tumors.

Authors:  M Kallajoki; K A Alanen; M Nevalainen; T J Nevalainen
Journal:  Prostate       Date:  1998-06-01       Impact factor: 4.104

7.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

8.  Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.

Authors:  Jiazhong Jiang; Blake Lee Neubauer; Jeremy R Graff; Marcio Chedid; James E Thomas; Neal W Roehm; Shaobo Zhang; George J Eckert; Michael O Koch; John N Eble; Liang Cheng
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

9.  Oncogenic action of secreted phospholipase A2 in prostate cancer.

Authors:  Paul Sved; Kieran F Scott; Duncan McLeod; Nicholas J C King; Jas Singh; Tania Tsatralis; Blagoy Nikolov; John Boulas; Laxman Nallan; Michael H Gelb; Mila Sajinovic; Garry G Graham; Pamela J Russell; Qihan Dong
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

10.  Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.

Authors:  Elena Kupert; Marshall Anderson; Yin Liu; Paul Succop; Linda Levin; Jiang Wang; Kathryn Wikenheiser-brokamp; Pingping Chen; Susan M Pinney; Trudy Macdonald; Zhongyun Dong; Sandra Starnes; Shan Lu
Journal:  BMC Cancer       Date:  2011-12-09       Impact factor: 4.430

View more
  2 in total

1.  Diagnostic Performance of Perfusion Computed Tomography for Differentiating Lung Cancer from Benign Lesions: A Meta-Analysis.

Authors:  Cuiqing Huang; Jianye Liang; Xueping Lei; Xi Xu; Zeyu Xiao; Liangping Luo
Journal:  Med Sci Monit       Date:  2019-05-11

2.  Comparison of Spectral and Perfusion Computed Tomography Imaging in the Differential Diagnosis of Peripheral Lung Cancer and Focal Organizing Pneumonia.

Authors:  Liangna Deng; Guojin Zhang; Xiaoqiang Lin; Tao Han; Bin Zhang; Mengyuan Jing; Junlin Zhou
Journal:  Front Oncol       Date:  2021-10-27       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.